Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC

Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors.

Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions

A structured low-GI Mediterranean diet, daily brisk walking, and vitamin D supplementation significantly reduced recurrence risk in HR-positive breast cancer survivors while improving metabolic health.

Adagio Files FDA Submission For Ventricular Ablation System

Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.

Ban Of Red Food Dye 3: Safety Implications For Families

FDA’s Red No. 3 ban will phase the dye out of foods and medicines by 2027, prompting reformulations while reassuring consumers about minimal health risk.

Reflow Medical’s Retrievable Coronary Drug‑Eluting Stent Shows Early Promise in In‑Stent Restenosis

Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options.